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ABSTRACT
Peritoneal carcinomatosis accompanied by malignant ascites is a major cause of 
death of advanced gastric cancer (GC). To comprehensively characterize the underlying 
genomic events involved in GC peritoneal carcinomatosis, we analyzed whole-exome 
sequences of normal gastric tissues, primary tumors, and malignant ascites from 
eight GC patients. We identified a unique mutational signature biased toward C-to-A 
substitutions in malignant ascites. In contrast, the patients who received treatment 
of adjuvant chemotherapy showed a high rate of C-to-T substitutions along with 
hypermutation in malignant ascites. Comparative analysis revealed several candidate 
mutations for GC peritoneal carcinomatosis: recurrent mutations in COL4A6, INTS2, 
and PTPN13; mutations in druggable genes including TEP1, PRKCD, BRAF, ERBB4, 
PIK3CA, HDAC9, FYN, FASN, BIRC2, FLT3, ROCK1, CD22, and PIK3C2B; and mutations 
in metastasis-associated genes including TNFSF12, L1CAM, DIAPH3, ROCK1, TGFBR1, 
MYO9B, NR4A1, and RHOA. Notably, gene ontology analysis revealed the significant 
enrichment of mutations in the Rho-ROCK signaling pathway-associated biological 
processes in malignant ascites. At least four of the eight patients acquired somatic 
mutations in the Rho-ROCK pathway components, suggesting the possible relevance 
of this pathway to GC peritoneal carcinomatosis. These results provide a genome-wide 
molecular understanding of GC peritoneal carcinomatosis and its clinical implications, 
thereby facilitating the development of effective therapeutics.
INTRODUCTION
To metastasize to distant organs, cancer cells 
exploit three major routes of dissemination: blood vessels, 
lymphatic vessels, and direct seeding into the body cavity 
[1]. In metastatic GC, direct seeding into the peritoneal 
cavity occurs in more than 55~60% of patients. The 
resulting peritoneal carcinomatosis is the most common 
and important clinical manifestation, leading to a poor 
prognosis [2, 3]. Once peritoneal dissemination takes 
place, it is regarded as incurable; it is seldom responsive 
to surgical resection and responds poorly to conventional 
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chemotherapy regimens, which cannot cross the blood-
peritoneal barrier [4]. Therefore, there is an unmet 
clinical need for the development of an effective therapy 
for peritoneal carcinomatosis, and it is important to 
comprehensively understand the molecular mechanisms 
involved in the peritoneal dissemination of GC cells.
Peritoneal carcinomatosis of GC is a complex and 
dynamic process involving multiple steps [5–7]. First, GC 
cells detach from a primary serosa-invasive tumor mass 
through the down-regulation of intercellular adhesion 
molecules, such as E-cadherin, and they then gain access 
to the peritoneal cavity [6]. Next, the free GC cells adhere 
to the distant mesothelium, the innermost monolayer of 
the peritoneum, through adhesion molecules such as CD44 
and selectins. After this attachment, the GC cells invade 
the subperitoneal connective tissue under the guidance of 
motility factors and matrix metalloproteinases [5]. Later, 
GC cells activate angiogenesis by secreting VEGF, and 
they proliferate to develop seeding nodules through the 
regulation of autocrine and paracrine loops involving 
growth factors and chemokines produced by GC cells and 
stromal cells [6]. 
It is currently well recognized that the accumulation 
of genetic alterations and the subsequent acquisition 
of phenotypic traits is responsible for the metastasis of 
various cancers [8, 9]. However, because most studies 
have focused on cellular and phenotypic changes involved 
in peritoneal metastasis, the genetic alterations responsible 
for the acquisition of these phenotypic traits have been 
poorly elucidated. 
Recent advances in next-generation sequencing have 
made whole-exome sequencing not only cost-effective 
but also technically feasible [10]. In particular, it is now 
possible to perform a genome-wide analysis of peritoneal 
carcinomatosis with small amounts of DNA obtained from 
malignant ascites, which is the most easily obtainable 
sample for metastatic GC by a simple paracentesis.
In this study, we aimed to identify genomic 
alterations of GC peritoneal carcinomatosis. To achieve 
this goal, we performed whole-exome sequencing using 
normal gastric tissues, primary tumors, and malignant 
ascites samples from eight GC patients with peritoneal 
carcinomatosis.
RESULTS
Clinicopathologic characteristics of GC patients 
with peritoneal carcinomatosis
Six of eight patients were diagnosed as diffuse-type 
GC with histological features that are consistent with 
poorly differentiated adenocarcinoma, whereas two patients 
were intestinal-type GC (Figure 1A). All patients had an 
advanced disease stage at the initial presentation (stage III 
or IV in AJCC 7th staging system) and received curative 
or palliative gastrectomy (Figure 1A). At the time when 
their diseases became metastatic or recurrent, all patients 
had clinically distinct peritoneal carcinomatosis with 
cytologically confirmed malignant ascites (Supplementary 
Figure 1). The median time from surgery to recurrence was 
3 months (range 0.7–50.9 months), and the median overall 
survival duration was 13.4 months (range 3.6–54.7 months) 
(Figure 1B).
Mutation patterns identified from primary 
tumors and malignant ascites
To explore somatic mutations involved in GC 
peritoneal carcinomatosis, we analyzed whole-exome 
sequences of 24 tissue samples that consist of triplets of 
normal gastric tissues, primary tumors, and malignant 
ascites from eight GC patients. Mutations identified 
are listed in Supplementary Table 1 and 2. When tumor 
purity was mathematically estimated using ASCAT v2.1, 
the average tumor purity was 24.0% in primary tumors 
and 45.5% in malignant ascites. The highly infiltrative 
feature of advanced diffuse-type GC may result in the 
low tumor purity, especially in primary tumors [11]. Our 
observation that the number of mutations in primary 
tumors significantly correlated with the average VAF 
(Supplementary Figure 2, r = 0.74, P = 0.037) may 
indicate that our mutation analysis may, in part, be affected 
by low tumor purity. 
The average sequencing depth of mutations in the 
protein-coding regions was ~61.1× in primary tumors 
and ~63.9× in malignant ascites. The average number of 
mutations per patient was ~27 in primary tumors and ~113 
in malignant ascites (Figure 2A). In particular, two patients 
P1 and P8 had hypermutation in malignant ascites, but 
not in primary tumors (Figure 2A). However, malignant 
ascites samples from the two patients were negative 
for a microsatellite instability test (Supplementary 
Figure  3). Instead, the hypermutation phenotype is 
most likely associated with chemotherapy. The two 
hypermutated patients received chemotherapy (FL (5-FU 
and leucovorin)/Docetaxel for P1 and FP (5-FU and 
cisplatin) for P8) before the collection of malignant 
peritoneal fluids, whereas other patients who do not have 
hypermutation had the treatment after the collection of 
malignant ascites. This result is consistent with a previous 
report that tumors treated with the chemotherapeutic drug 
temozolomide were hypermutated [12].
To dissect a mutational signature of primary tumors 
and malignant ascites, we examined the spectrum of 
base substitutions. The analysis revealed an unusual high 
proportion of C-to-A transversions during the progression 
from primary tumors to malignant ascites, with the 
exception of the two hypermutated patients (P1 and P8) 
(Figure 2A and 2B). On average, C-to-A transversions 
accounted for ~39.3% in primary tumors, and ~59.4% 
(except for hypermutated patients) in malignant ascites 
(Figure 2B, left panel).
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To assess whether the C-to-A transversion is a 
general mutational signature that occurs in ascites, we 
additionally performed whole-exome sequencing of benign 
ascites derived from three liver cirrhosis patients. Despite 
the non-cancerous characteristics of the samples, a small 
number of somatic mutations were identified in the three 
liver cirrhosis-derived ascites: 10 mutations in patient N1; 
no mutations in patient N2; and 15 mutations in patient 
N3 (Supplementary Table 3). Although we cannot rule out 
the possibility that the small number of mutations may be 
background errors, the proportion of C-to-A transversions 
in liver cirrhosis-derived benign ascites was as high as 
84% (21 of 25 mutations) (Figure 2B, left panel).
Next, we compared distinct mutational patterns 
between hypermutated (P1 and P8) and the other non-
hypermutated samples. Hypermutated malignant ascites 
exhibited a higher proportion of C-to-T transitions 
(43.0%) and a lower proportion of C-to-A transversions 
(16.7%) compared to non-hypermutated malignant 
ascites (22.2% C-to-T transitions and 59.4% C-to-A 
transversions) (Figure 2B, right panel). In addition, the 
examination of 96 base substitutions displayed a distinct 
base substitution signature: non-hypermutated malignant 
ascites exhibited a biased base substitution pattern 
toward C[C→A]G, C[C→A]C, C[C→A]A, C[C→A]
T, T[C→A]G, and T[C→A]A tri-nucleotide contexts 
(Supplementary Figure 4). 
Somatic mutations and their clinical associations
Mutations relevant to a metastatic process may be 
positively selected and accumulated during metastasis in a 
time-dependent manner [13]. Therefore, we hypothesized 
that a longer time interval from gastrectomy to peritoneal 
carcinomatosis would increase the chance for numerous 
mutations to be accumulated in malignant ascites. 
To test this hypothesis, we assessed the correlation 
between the number of mutations and the elapsed time 
from gastrectomy to the development of peritoneal 
carcinomatosis (the length between S and F in Figure 1B). 
Two patients with hypermutation were excluded from 
this analysis because they may have distinct mutagenic 
processes from non-hypermutated patients as shown in 
Figure 2B. We observed a tendency toward a positive 
correlation between the number of mutations in malignant 
ascites and the time interval from gastrectomy to the 
development of peritoneal carcinomatosis (Supplementary 
Figure 5A, r = 0.74, P = 0.086). We also hypothesized 
that the population of tumor cells harboring mutations 
may expand in malignant ascites due to the growth 
advantage provided by mutations, thereby resulting in a 
time-dependent increase of mutational VAFs in malignant 
ascites. We observed a significant positive correlation 
between mutational VAFs in malignant ascites and the 
elapsed time from gastrectomy to the development of 
Figure 1: Clinical information. (A) Clinicopathologic characteristics of eight GC patients with peritoneal carcinomatosis. PD, poorly-
differentiated; SRC, signet ring cell. (B) Clinical time course of eight GC patients with peritoneal carcinomatosis. Numbers indicate the 
time interval (in months) from the time of surgery (S). D, time of death; F, time of ascites fluid collection; R, time of recurrence.
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peritoneal carcinomatosis (Supplementary Figure 5B, 
r = 0.79, P =  0.045). However, these correlation patterns 
were not observed with mutation profiles of primary 
tumors (Supplementary Figure 5C and 5D)
Some mutations found in malignant ascites would 
be associated with poor disease prognosis because tumor 
cells harboring these mutations overcame multiple 
metastatic barriers. Therefore, we tested whether the 
increased number and VAFs of mutations in malignant 
ascites correlate with survival duration after peritoneal 
carcinomatosis (the length between F and D in Figure 1B). 
The number and VAFs of mutations in the malignant 
ascites showed a mild negative correlation trend with 
overall survival duration after peritoneal carcinomatosis 
(Supplementary Figure 5E and 5F). These negative 
correlation trends were not observed with mutation profiles 
of primary tumors (Supplementary Figure 5G and 5H). 
Biological processes targeted by mutations
We examined biological processes frequently mutated 
in primary tumors and malignant ascites. Consistent with 
a previous report [14], genes involved in cell adhesion and 
chromosome organization were frequently mutated in our 
GC patients as well. In primary tumors, genes involved in 
cell adhesion, collagen organization, axonogenesis, cell 
motility, and cell morphogenesis were frequently mutated 
(Figure 3). In malignant ascites, functional terms, such 
as actin cytoskeleton, chromosome organization, focal 
adhesion, Rho-protein signaling, immune activation, 
and apoptosis, were significantly overrepresented to be 
biological processes affected by mutations (Figure 3). 
The enrichment of the Rho signaling pathway-associated 
functional terms, such as actin cytoskeleton, focal 
adhesion, and Rho-protein signaling, may suggest the 
importance of the Rho signaling pathway in GC peritoneal 
carcinomatosis. 
Clonality of primary tumors and malignant 
ascites
A recent study revealed that primary tumors and the 
matched metastases share a majority of mutations [15], 
exhibiting a high mutational concordance between them. 
However, since malignant ascites from our patients were 
formed after curative or palliative gastrectomy followed 
by recurrence (Figure 1A), it is unlikely that our primary 
tumors and the matched malignant ascites would exhibit 
a high mutational concordance. In fact, the genomic 
concordance between them was relatively low compared 
to the previous synchronous metastasis study (Figure 
4A, range 0–38%). Instead, malignant ascites-specific 
mutations accounted for the highest proportion in our 
tumor samples (Figure 4A, range 15–93%). 
Figure 2: Statistical analyses of somatic mutations. (A) The number and base substitutions of mutations. PT, primary tumor; A, 
malignant ascites (B) The proportion of base substitutions found in primary tumors and ascites. N, normal tissues; T, primary tumors; MA, 
malignant ascites; L, normal blood; BA, benign ascites. 
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To infer the clonality of primary tumors and 
malignant ascites, we performed SciClone analysis. 
Two patients, P2 and P3, were excluded from this 
analysis because these patients had too small number of 
mutations to cluster. Consistent with the low genomic 
concordance, clonality patterns between primary tumors 
and malignant ascites were largely different (Figure 4B). 
Some patients exhibited an increased clonality during 
metastasis, whereas the others showed decreased or similar 
clonality (Figure 4B), revealing the heterogeneous clonal 
evolution during metastasis. Patients (P4 and P7), who 
exhibited increased clonality during metastasis, showed 
low genomic concordance between primary tumors and 
malignant ascites, whereas a patient P6, who exhibited 
decreased clonality during metastasis showed the relatively 
high genomic concordance (Figure 4A and 4B). This 
pattern is consistent with a recent report that the genomic 
concordance between primary tumors and metastases is 
associated with clonality change [16]. Accordingly, these 
results suggest that gastrectomy followed by recurrence 
may alter the clonal composition of the tumors, although 
we cannot completely rule out the issue of low tumor purity 
in primary tumors.
Next, we examined the clinical implication of 
tumor clonality. A previous study showed that patients 
exhibiting high clonality had poor prognosis in GC 
[17]. Consistent with this observation, higher clonality 
in primary tumors showed a trend of faster development 
of peritoneal calcinomatosis after gastrectomy 
(Supplementary Figure 6A, r = −0.62). Higher clonality in 
malignant ascites exhibited a trend toward poorer overall 
survival after peritoneal carcinomatosis (Supplementary 
Figure 6B, r = −0.44). In addition, increased clonality 
during metastasis positively correlated with longer time 
interval from gastrectomy to peritoneal carcinomatosis 
(Supplementary Figure 6C, r = 0.68) and negatively 
correlated with overall survival after peritoneal 
carcinomatosis (Supplementary Figure 6D, r = −0.71).
Figure 3: Biological processes frequently mutated in primary tumors and malignant ascites. The functional terms 
significantly overrepresented are presented as -log10 (P-value). 
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Figure 4: Clonality of primary tumors and malignant ascites. (A) The number of shared (between primary tumors and malignant 
ascites) and tumor type-specific mutations. (B) Clonality of primary tumors and malignant ascites analyzed by SciClone. Number (n) 
indicates the number of clonal clusters. 
Oncotarget8061www.impactjournals.com/oncotarget
Druggable genes mutated in each patient
We performed two-dimensional clustering of 
mutations using SciClone (Figure 5). To provide therapeutic 
options for each patient, we investigated whether tumor 
clones analyzed by clustering are therapeutically targetable. 
We employed Drug-Gene interaction database (DGIdb) 
to search for druggable genes. In patient P1, two clonal 
clusters emerged in malignant ascites (Figure 5). One of 
the two emerging clones may be targetable by TEP1 (e.g. 
GRN163L) or PRKCD (e.g. KAI-9803) inhibitors (Figure 5 
and Supplementary Table 4). In patient P4, two of four 
malignant ascites-emerging clones may be targetable by 
inhibitors against BRAF (e.g. Vemurafenib), TEP1, ERBB4, 
PIK3CA, HDAC9, or FYN (Figure 5 and Supplementary 
Table 4). In patient P6, FASN may be a druggable target 
for a malignant ascites-emerging clone (Figure 5 and 
Supplementary Table 4). In patient P8, inhibitors against 
BIRC2 or FLT3, or a monoclonal antibody against CD22 
may be potential drugs for two malignant ascites-emerging 
clones (Figure 5 and Supplementary Table 4). However, 
we predict that the patient 8 may be resistant to the drug 
treatment because of the highly heterogeneous clonality.
Somatic mutations found in GC peritoneal 
carcinomatosis
We found numerous mutations in GC peritoneal 
carcinomatosis (Supplementary Tables 1 and 2) and 
successfully confirmed a few of them by Sanger 
sequencing (Supplementary Figures 7 and 8). In particular, 
we identified three recurrent mutations that occurred at the 
same genomic position in two malignant ascites samples. 
A COL4A6 mutation was identified at genomic position 
107431221 on the X chromosome in patients P4 and P5 
(Figure 6 and Supplementary Figure 8). This mutation is 
a nonsense mutation (G543*) that introduces a premature 
stop codon at amino acid 543 of COL4A6 (Figure 7A). 
Because this mutation potentially truncates ~68% of the 
COL4A6, including the collagen helix and C4 domains 
(Figure 7A), it may lead to the functional loss of COL4A6. 
COL4A6 mutations were identified in 3% of the TCGA GC 
patients (6 of 220 patients). A second recurrent mutation 
was an INTS2 mutation that was located at genomic 
position 59949712 on chromosome 17 in patients P2 and 
P4 (Supplementary Figure 8). This mutation is a missense 
mutation that changes a glutamine at amino acid 906 to a 
lysine (Figure 7A). In total, 3% of the TCGA GC patients 
(6 of 220 patients) acquired INTS2 mutations. Lastly, 
a PTPN13 mutation was identified at genomic position 
87687597 on chromosome 4 in patients P1 and P8 (Figure 
6 and Supplementary Figure 8). This mutation is a missense 
mutation (L1424P) located in a protein-interacting PDZ 
domain (Figure 7A) and has a high probability of being 
functionally deleterious, as predicted by Mutation Assessor 
(prediction score = 3.74) [18]. PTPN13 mutations were 
found in 6% of the TCGA GC patients (12 of 220 patients). 
Notably, GC patients harboring COL4A6, INTS2, or 
PTPN13 mutations exhibited a worse survival probability 
than patients lacking mutations in the genes in the TCGA 
GC cohort (Figure 7B). 
In addition, at least four of eight malignant ascites 
samples acquired mutations in the Rho-ROCK pathway 
components. In patient P7, we identified a RHOA mutation 
encoding the L57V substitution (Figure 6). The RHOA 
L57V mutation was recently identified to be a hotspot 
mutation for diffuse-type GC [13, 19, 20]. In patient P3, 
we identified a ROCK1 nonsense mutation (Figure 6). 
Figure 5: Two dimensional clustering of mutations presented as primary tumors versus malignant ascites. Druggable 
genes are indicated by arrows on the basis of the DGIdb. 
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This mutation introduces a premature stop codon at the 
285th amino acid of ROCK1, leading to the truncation of 
~79% of ROCK1. The truncated portion includes a part 
of the kinase domain (aa 76–338), the HR1 Rho-binding 
repeat (aa 458–537), the entire Rho-binding domain 
(aa 948–1014), and the PH domain (aa 1119–1317). The 
lack of a Rho-binding domain by the ROCK1 mutation 
could impair the Rho-ROCK pathway similarly to the 
RHOA L57V mutation. In patient P4, we identified a 
missense mutation (E1516K) in MYO9B (Figure 6), a 
RhoGAP with inhibitory activity against RhoA [21]. 
This mutation is predicted to be deleterious by Mutation 
Assessor (prediction score = 2.28). A mutation (W192L, 
prediction score = 2.19) in FYN, a regulator of RhoA 
activity [22], was also identified in patient P4 (Figure 6). 
We also identified a ROCK2 mutation (S457N) in patient 
P1 (Figure 6). Accordingly, these results may suggest 
the importance of the Rho-ROCK pathway in peritoneal 
carcinomatosis. 
We next examined mutations found in metastasis-
associated genes. In patient P2, we identified a mutation 
in TNFSF12 (Figure 6, P284Q, prediction score = 1.85) 
that plays a role in metastasis by upregulating VEGF 
through the NF-κB signaling pathway [23]. We also 
identified a mutation in L1CAM in patient P2 (Figure 6, 
G574W, prediction score = 2.47) that was demonstrated 
to be a relevant metastatic mediator targeted by plasmin 
[24]. A DIAPH3 mutation (Figure 6, R144L, prediction 
score = 1.91) was also identified in patient P2. DIAPH3 
plays roles in cancer cell invasion, amoeboid cell behavior, 
and metastasis in vivo [25]. As predicted by Mutation 
Assessor, all these mutations have a high probability of 
being functionally deleterious. 
We also found two mutations in the TGF-β  pathway 
genes. One was a TGFBR1 mutation (Figure 6, K232N, 
prediction score = 5.08) in patient P3, and the other 
was a mutation in NR4A1 (Figure 6, P135S, prediction 
score = 1.55) in patient P6, which activates metastatic 
progression in a TGF-β-dependent manner [26]. 
DISCUSSION
Here, we performed whole-exome sequencing to 
identify somatic mutations involved in GC peritoneal 
carcinomatosis. Recently published genomic analyses 
focused entirely on the primary tumor mass [13, 27, 28]. 
These studies provided limited information regarding 
the metastatic disease after recurrence. To address this 
issue, we used intraperitoneal metastatic tumor cells by 
characterizing their genomic features through whole-
exome sequencing.
We observed a unique base substitution signature 
biased toward C-to-A transversions in GC-derived 
malignant ascites. Interestingly, mutations detected from 
liver cirrhosis-derived benign ascites also presented 
predominant C-to-A transversions. Accordingly, these data 
may suggest that unknown mutagenic processes within 
ascitic fluid might promote C-to-A conversion. However, 
the result should be interpreted with caution, because 
the average VAF of the benign ascites-derived mutations 
detected was as low as ~9.3%. Although the mutation-
calling software MuTect can detect mutations with VAFs 
as low as 10% and below with high sensitivity [29], it is 
required to confirm our result using a large sample set 
whether the biased C-to-A substitution is a characteristic 
of ascites-derived mutations.  
The number and VAF of mutations, and tumor 
clonality showed a trend of correlation with the elapsed 
time between gastrectomy and the development of 
peritoneal carcinomatosis, and the overall survival 
Figure 6: Paired VAFs of mutations in primary tumors and malignant ascites. Scatter plots presented as VAFs in malignant 
ascites versus VAFs in primary tumors. Metastasis-associated mutations are indicated by arrows.
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duration after peritoneal carcinomatosis. However, given 
the low tumor purity, especially in primary tumors, we 
cannot rule out the possibility that the correlation pattern 
is false positive. Therefore, validation with a large sample 
set is required to claim that time course of clinical events 
such as the development of peritoneal carcinomatosis and 
overall survival can be estimated by mutation profiles. 
Whole-exome sequencing revealed several candidate 
mutations in GC peritoneal carcinomatosis: mutations in 
druggable genes (TEP1, PRKCD, BRAF, ERBB4, PIK3CA, 
HDAC9, FYN, FASN, BIRC2, FLT3, ROCK1, CD22, 
and PIK3C2B) and mutations in metastasis-associated 
genes (PTPN13, TNFSF12, L1CAM, DIAPH3, ROCK1, 
TGFBR1, MYO9B, NR4A1, and RHOA). We also identified 
recurrent mutations in COL4A6, INTS2, and PTPN13. 
The COL4A6 nonsense mutation (G543*) may result in 
the loss-of-function of COL4A6 because the mutation 
truncates ~68% of the COL4A6 protein. The functional 
loss of COL4A6, a type IV collagen found in the basement 
membrane, could disrupt the cell-matrix interaction and 
enhance cell invasion and metastasis [30, 31]. PTPN13 
was reported to inhibit metastasis by dephosphorylation of 
Src or Her2 [32]. Our study provides a preliminary result, 
but validation experiments are required to prove whether 
the recurrent mutations frequently occur in malignant 
ascites. Therefore, the mutations should be validated with 
high detection sensitivity using high quality samples. 
Interestingly, by searching for the TCGA mutation data, 
we found a hepatocellular carcinoma patient harboring the 
INTS2 recurrent mutation (G906K). 
We found somatic mutations in the Rho-ROCK 
pathway genes, including RHOA, ROCK1, ROCK2, FYN, 
and MYO9B. Our gene ontology analysis revealed that 
the Rho-ROCK pathway-associated functional terms, 
including actin cytoskeleton, focal adhesion, and the Rho-
protein signaling, were significantly overrepresented in the 
mutated genes in malignant ascites (Figure 3). A recent 
study demonstrated that the overexpression of mutant 
RhoA harboring an L57V mutation resulted in evasion of 
cell detachment-induced apoptosis, referred to as anoikis 
[13]. Since the capability for anchorage-independent 
growth and resistance against anoikis may be a prerequisite 
for the survival of tumor cells during metastasis, this 
RHOA mutation may provide a selective advantage for 
metastasis. We identified a nonsense mutation in ROCK1 
that introduces a premature stop codon at amino acid 285. 
This mutation may cause the loss-of-function of ROCK1, 
because most of the functional domains, including the 
Rho-binding domain, are truncated by the mutation. 
Given that treatment with the ROCK inhibitor Y-27632 
prevents anoikis [13], tumor cells harboring the ROCK1 
nonsense mutation might be resistant to anoikis through 
the impairment of the Rho-ROCK pathway, similar to 
tumor cells harboring the RHOA L57V mutation. 
We identified somatic mutations in TGFBR1 and 
NR4A1, which are associated with the TGF-β pathway. 
Contrary to a tumor suppressive role in early-stage cancer, 
the TGF-β pathway contributes to tumor invasion and 
metastasis through epithelial-mesenchymal transition 
(EMT) in advanced cancer [33]. A recent study reported that 
Figure 7: Recurrent mutations in COL4A6, INTS2, and PTPN13. (A) The positions of COL4A6, INTS2, and PTPN13 mutations 
found in four different GC studies. (B) Kaplan-Meier survival curves analyzed by the absence or presence of COL4A6, INTS2, and PTPN13 
mutations in the TCGA GC dataset. The log rank P-value is shown.
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NR4A1 activated the TGF-β-induced EMT and promoted 
metastasis through AXIN2- RNF12/ARKADIA-induced 
SMAD7 degradation [26]. Therefore, further studies are 
required whether the NR4A1 mutation participates in the 
development of peritoneal carcinomatosis.
Our study revealed the genetic alterations and their 
clinical associations in GC peritoneal carcinomatosis 
through whole-exome sequencing of malignant ascites. 
However, there are several limitations, including the 
small sample size, the relatively low sequencing depth, 
low tumor purity of primary tumors, and a lack of 
functional validation. In the future, deep sequencing 
with a large sample set and subsequent functional studies 
would support our results, facilitating the discovery of 
therapeutic targets against GC peritoneal carcinomatosis. 
MATERIALS AND METHODS
Sample collection
Surgical specimens of primary gastric tumors and 
their matched normal gastric tissues (non-malignant) 
were harvested and fresh frozen in Yonsei Cancer Center 
(Seoul, Korea). The normal gastric tissues used in this 
study were harvested from gastric regions at a distance 
from the primary tumor and exhibited no evidence of 
metaplasia and dysplasia. Matched malignant ascites were 
collected through paracentesis or catheter drainage of GC 
patients, whereas non-malignant ascites were obtained 
from patients with liver cirrhosis. The clinicopathologic 
characteristics were retrospectively reviewed based on the 
electronic medical records of the patients. Pathological 
diagnosis and staging were conducted according to the 
American Joint Committee on Cancer 7th staging system. 
This study was performed with the approval of the 
institutional review board.
Whole-exome sequencing and data analysis
Genomic DNA was isolated from 24 tissues using 
the Puregene™ DNA purification kit (Qiagen, Venlo, 
Netherlands). Library construction and targeted exome 
enrichment were performed using the Illumina TruSeq 
DNA Sample Prep Kit (San Diego, CA, USA) and the 
SeqCap EZ Human Exome Library v2.0 kit (Roche 
NimbleGen, WI, USA), respectively. Next, paired-end 
sequencing was performed on the Illumina HiSeq 2000 
sequencing instrument, according to the manufacturer’s 
instructions, yielding ~100 bp-sized short sequencing 
reads. The sequencing reads were aligned on human 
reference genome 19 using Burrows Wheelers Aligner 
[34], and duplicates reads were removed using Picard 
(Broad Institute). Then, the remaining reads were calibrated 
and realigned using Genome Analysis Toolkit [35]. The 
realigned BAM files were analyzed using MuTect [29] and 
Strelka [36] to detect somatic single-nucleotide variants 
and insertions/deletions, respectively. Coding variants were 
selected by dbNSFP annotation [37] and germline variants 
were filtered out by dbSNP database (dbSNP version 
132). SciClone was used to infer tumor clonality [38], and 
ASCAT v2.1 was used to estimate tumor purity [39]. We 
run all these programs under the default parameter settings. 
Data access
Our exome sequencing raw files are available from 
the NCBI SRA (http://www.ncbi.nlm.nih.gov/sra/) via 
accession number SRP043661.
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